Home
JournalsCollections
For Authors For Reviewers For Editorial Board Members
Article Processing Charges Open Access
Ethics Advertising Policy
Editorial Policy Resource Center
Company Information Contact Us
OPEN ACCESS

Liver Dysfunction in Adult COVID-19 Infection—A Comparison of the Delta Variant and Predecessor Strains

  • Ruveena Bhavani Rajaram1,* ,
  • Ram Prasad Sinnanaidu1,
  • Xin Hui Khoo1,
  • Nisha Puvanendran1,
  • Anjanna Kukreja2,
  • Bushra Megat Johari2,
  • Sazali Basri2,
  • Rong Xiang Ng2,
  • Hang Cheng Ong2,
  • Pui Li Wong2,
  • Sharifah Faridah Syed Omar2,
  • Shasheela Ponnampalavanar2 and
  • Sanjiv Mahadeva1
Journal of Translational Gastroenterology   2023;1(2):57-66

doi: 10.14218/JTG.2023.00034

Received:

Revised:

Accepted:

Published online:

 Author information

Citation: Rajaram RB, Sinnanaidu RP, Khoo XH, Puvanendran N, Kukreja A, Johari BM, et al. Liver Dysfunction in Adult COVID-19 Infection—A Comparison of the Delta Variant and Predecessor Strains. J Transl Gastroen. 2023;1(2):57-66. doi: 10.14218/JTG.2023.00034.

Abstract

Background and objectives

Multiple factors are responsible for severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2)-associated liver dysfunction. The impact of variants of concern (VoCs) on liver function is less clear. The aims were to determine (1) the prevalence and risk of abnormal liver biochemistry (ALB) and liver injury (LI) and (2) differences in ALB and LI with the Delta variant compared with wild-type and VoCs before Delta variant coronavirus disease of 2019 (COVID-19) infections in Malaysian adults.

Methods

This prospective single-center, observational study enrolled adults hospitalized for COVID-19 infection between 1 February 2020 and 30 October 2021 using a convenience sampling method. Patients with COVID-19 confirmed by real-time reverse-transcriptase polymerase chain reaction of nasal and pharyngeal swabs and having at least one liver function test were recruited and assigned to cohort A (wild-type strain and all VoCs before the Delta variant) or cohort B (Delta variant).

Results

Of 1,246 patients with COVID-19 infection, 58.7% developed ALB and 26.6% developed LI. Multivariate analysis showed that men, moderate and severe disease, and underlying chronic liver disease (CLD) were associated with ALB and LI. Patients with the Delta variant had a significantly higher risk of developing both ALB (71.6% vs. 48.5%, p < 0.001) and LI (38.8% vs. 17.1%, p < 0.001) compared with previous strains.

Conclusions

ALB was more common than LI, but LI was more frequent in men with underlying CLD, and in those with moderate or severe COVID-19 infections. Patients with Delta variant infections were more likely to have ALB and LI than those with precedent strains.

Keywords

COVID-19 infection, SARS-CoV 2, Delta variant, Liver dysfunction, Liver injury

Introduction

In December 2019, the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) virus spread globally to the extent of becoming a pandemic. In Malaysia, the first confirmed case of coronavirus disease of 2019 (COVID-19) was detected on 23 February 2020 and until now there have been 3.5 million cases nationwide, with a lower mortality rate of 0.91%.1 Over 2 years, multiple variants of the original virus have emerged. Variants of concern (VoCs) include Alpha, Beta, Gamma, Delta, and Omicron.2 The Delta variant is recognized as more infective than the other VoCs and causes more severe infections and more deaths.3–5 The first case of Delta variant infection was detected in Malaysia on 19 April 2021 and continued to be the predominant strain until January 2022.1

SARS-CoV-2 is known to primarily cause upper respiratory tract infections that lead to lower respiratory tract infections in a subset of patients, causing alveolar damage and subsequent respiratory failure.6–8 Although respiratory tract involvement is the prominent clinical manifestation, liver dysfunction in COVID-19 patients is a recognized entity, and the cause of this phenomenon is multifactorial.9–15 The incidence of abnormal liver biochemistry (ALB) is common (14–76.3%) and varies widely among populations.11–14,16–18 These studies also revealed that disease severity, increasing age, and underlying chronic liver disease (CLD) were factors that increased the risk of liver injury (LI). However, data on the extent of liver dysfunction caused by different VoCs are lacking. There is also a paucity of local data regarding factors that increase the risk of liver dysfunction in people with COVID-19 infection. This study aimed to determine (1) the prevalence and risk factors of ALB and LI in adult COVID-19 patients and (2) the differences of ALB and LI in patients with the Delta variant compared with the wild-type and all VoCs that appeared prior to the Delta variant in Malaysia.

Materials and methods

Study design and participants

This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Research Ethics Committee of University of Malaya (MECID No. 202146-10036). All subjects gave written informed consent. We performed a prospective observational study and recruited patients who were admitted between 1 February 2020 and 30 October 2021 using a convenience sampling method. Patients 18 years of age and older who were admitted to one hospital in Malaysia with laboratory-confirmed COVID-19 confirmed by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swab specimens and had at least a single liver function test (LFT) during hospitalization were recruited into the study. Patients were divided into cohort A (admission between February 2020 and 30 April 2021), which included the COVID-19 wild-type strain and all VoCs before the Delta variant and cohort B (admission between 1 May 2021 and 31 October 2021), which included COVID-19 Delta variant cases. Owing to lack of genomic sequencing, COVID-19 cases detected from May 2021 onwards were presumed to be of the Delta variant, as the first case of Delta variant infection in Malaysia was detected on 12 April 2021 and cases increased rapidly from May 2021 onward.

Data collection

Relevant clinical data, laboratory, and imaging results were obtained by reviewing the electronic medical record of the patients. Information regarding the presence of liver disease diagnosed either before or during admission, pharmacotherapy, disease severity, and outcome were documented. CLD was defined when a patient had a diagnosis of liver cirrhosis, chronic hepatitis B, or C infection, alcoholic liver disease, nonalcoholic steatohepatitis, and/or autoimmune liver disease.

ALB was defined and categorized into hepatocellular type when alanine aminotransaminase (ALT) or aspartate aminotransferase (AST) was more than 40 U/L, cholestatic type when alkaline phosphatase (ALP) was more than 130 U/L or gamma-glutamyl transferase (GGT) was more than 50 U/L, or mixed type if both patterns were present. LI was defined and categorized as hepatocellular if AST or ALT was more than three times the upper limit of normal, cholestatic type if ALP or GGT or total bilirubin was more than two times the upper limit of normal, or mixed if both patterns were present. For patients with more than one LFT result during hospitalization, the most deranged LFT result was documented. COVID-19 disease severity was categorized as mild (category 1–2), moderate (category 3), or severe (category 4–5). Definitions of the categories were: category 1, asymptomatic COVID-19 patients; category 2, symptomatic patients with no evidence of pneumonia and not requiring oxygen support; category 3, patients with clinical or radiological evidence of pneumonia but not requiring oxygen support; category 4, patients with pneumonia and requiring oxygen support; and category 5, patients requiring mechanical ventilation or with organ failure.

Statistical analysis

Categorical variables were reported as numbers and percentages. Chi-square and Fisher’s exact tests were used to compare categorical variables. Continuous values were reported as means (standard deviations) and were compared with Student’s t-test or one-way analysis of variance for parametric data. Continuous values were reported as medians and were compared with Mann-Whitney U or Kruskal-Wallis H tests for nonparametric data. Multivariate analysis was performed using multiple linear regression. The statistical analyses were performed with SPSS version 21 (IBM Corp., Armonk, NY, USA). A two-sided significance level of p ≤ 0.05 was used for all models.

Results

We included 1,246 patients, 697 (58.7%) in cohort A and 549 (44.1%) in cohort B who were admitted to our hospital with COVID-19 infection between 1 February 2020 and 30 October 2021. The median age was 50.0 years with a male:female ratio of 1:1.02. More than half (52.1%) had mild disease and 47.1% were given specific treatment. CLD was present in 11.7% of patients. The baseline and clinical characteristics of these patients are outlined in Table 1.

Table 1

Demographics and clinical characteristics of COVID-19 patients (n = 1,246)

CharacteristicCohort*
p-value
All, n = 1,246Cohort A, n = 697Cohort B, n = 549
Age in years
Median [IQR]50.0 (31)44.0 (31)55.0 (27)<0.001
  1–60846 (67.9)508 (72.9)338 (61.6)<0.001
  >60400 (32.1)189 (27.1)211 (38.4)
Sex
  Male618 (49.6)325 (46.6)256 (53.4)0.018
  Female628 (50.4)372 (53.4)293 (46.6)
Ethnicity
  Malay779 (62.5)427 (61.3)352 (64.1)0.123
  Chinese233 (18.7)126 (18.1)107 (19.5)
  Indian189 (15.2)112 (16.1)77 (14.0)
  Others45 (3.6)32 (4.6)13 (2.4)
COVID-19 severity
  Mild649 (52.1)450 (64.6)199 (36.2)<0.001
  Moderate200 (16.1)108 (15.5)92 (16.8)
  Severe397 (31.9)139 (19.9)258 (47.0)
Disease-modulating pharmacotherapy
  Yes587 (47.1)231 (33.1)356 (64.8)<0.001
  No659 (52.9)466 (66.9)193 (35.2)
Type of treatment
  NSAID81 (6.5)68 (12.4)13 (1.9)<0.001
  Hydroxychloroquine25 (2.0)22 (3.2)3 (0.5)0.001
  Favipiravir175 (14.0)56 (8.0)119 (21.7)<0.001
  Methylprednisolone121 (9.7)40 (5.7)81 (14.8)<0.001
  Clexane273 (21.9)73 (10.5)200 (36.4)<0.001
  Tocilizumab110 (8.8)48 (6.9)62 (11.3)0.006
  Dexamethasone455 (36.5)164 (23.5)291 (53.0)<0.001
  Baricitinib5 (0.4)0 (0.0)5 (0.9)0.012
Comorbidities
  CLD146 (11.7)75 (10.8)71 (12.9)0.237
  NAFLD126 (10.1)67 (9.6)59 (10.7)0.510
  DM388 (31.1)179 (25.7)209 (38.1)<0.001
  HTN441 (35.4)205 (29.4)236 (43.0)<0.001
  CKD91 (7.3)44 (6.3)47 (8.6)0.130
  CCF74 (5.9)42 (6.0)32 (5.8)0.884
  Chronic lung disease86 (6.9)42 (6.0)44 (8.0)0.169
  Cancer51 (4.1)31 (4.4)20 (3.6)0.477
ALB
  Yes731 (58.7)338 (48.5)393 (71.6)<0.001
  No515 (41.3)359 (51.5)156 (28.4)
Type of ALB
  Hepatocellular205 (16.5)116 (16.6)89 (16.2)<0.001
  Cholestasis80 (6.4)46 (6.6)34 (6.2)
  Mixed446 (35.8)176 (25.3)270 (49.2)
Deranged LFT
  Total bilirubin153 (21.2)61 (18.3)92 (23.6)0.084
  ALP135 (18.8)59 (18.0)76 (19.4)0.620
  ALT475 (65.1)192 (57.0)283 (72.0)<0.001
  AST583 (82.3)237 (75.0)346 (88.3)<0.001
  GGT391 (54.4)162 (49.2)229 (58.7)0.011
Liver injury
  Yes332 (26.6)119 (17.1)213 (38.8)<0.001
  No914 (73.4)578 (82.9)336 (61.2)
Type of liver injury
  Hepatocellular54 (4.3)27 (3.9)27 (4.9)<0.001
  Cholestasis149 (12.0)54 (7.7)95 (17.3)
  Mixed123 (9.9)37 (5.3)86 (15.7)
Abnormal LFT
  Total bilirubin86 (26.2)30 (25.4)56 (26.7)0.806
  ALP100 (30.3)39 (33.1)61 (28.8)0.418
  ALT267 (80.4)86 (72.3)181 (85.0)0.005
  AST306 (94.4)102 (91.1)204 (96.2)0.054
  GGT291 (88.4)97 (82.9)194 (91.5)0.019
Liver failure
  Yes14 (1.1)7 (1.0)7 (1.3)0.653
  No1,232 (98.9)690 (99.0)542 (98.7)
ICU admission
  Yes172 (13.8)84 (12.1)88 (16.0)0.043
  No1,074 (86.2)613 (87.9)461 (84.0)
Ventilator
  Yes354 (28.4)123 (17.6)231 (42.1)<0.001
  No892 (71.6)574 (82.4)318 (57.9)
Death
  Yes61 (4.9)28 (4.0)33 (6.0)0.105
  No1,185 (95.1)669 (96.0)516 (94.0)

Prevalence and risk factors for ALB and LI

ALB was seen in 731 (58.7%) patients, but only 26.6% experienced LI and 14 (1.1%) patients had liver failure. Mixed type and cholestasis were the predominant patterns of liver insult seen among patients with ALB and LI, respectively; specifically, 69.3% above 60 years and 72% of male patients had ALB, and incidence increased with disease severity, and 78% of patients who received any disease-modulating pharmacotherapy had ALB. Notably, the majority of patients with comorbidities who required intensive care unit (ICU) admission, or died were found to have ALB as well (Table 2). Multivariate analysis showed a significantly higher risk of developing ALB in men (OR = 2.93, 95% CI: 2.24, 3.83), patients with moderate (OR = 1.66, 95% CI: 1.10, 2.50) or severe (OR = 3.17, 95% CI: 1.53, 6.57) disease, CLD (OR = 19.31, 95% CI: 2.38, 156.53), or hypertension (HTN) (OR = 1.64, 95% CI: 1.16, 2.33). In total, 34.8% of patients older than 60 years of age and 43.8% who received disease-modulating pharmacotherapy were reported to have LI. The frequency of LI also increased with disease severity. The majority of patients who required mechanical ventilation, ICU admission, or died also had LI (Table 3). Multivariate analysis for LI showed significantly higher frequencies in men (OR = 1.79, 95% CI: 1.33, 2.41), in patients with moderate (OR = 3.03, 95% CI: 1.87, 4.92) or severe (OR = 4.56, 95% CI: 2.27, 9.18) disease, or CLD (OR = 2.93, 95% CI: 1.04, 8.28). The risk was lower in Indian patients (OR = 0.61, 95% CI: 0.39, 0.95) compared with other ethnic groups.

Table 2

Multivariate analysis of COVID-19 patients with abnormal liver biochemistry (n = 731)

CharacteristicsOverall
Cohort A
Cohort B
Abnormal Liver Biochemistry
AOR (95% CI)p-valueAbnormal Liver Biochemistry
AOR (95% CI)p-valueAbnormal Liver Biochemistry
AOR (95% CI)p-value
YesNoYesNoYesNo
Age in years
  ≤60454 (53.7)392 (46.3)219 (43.1)289 (56.9)1.08 (0.65, 1.80)0.770235 (69.5)103 (30.5)1.85 (1.05, 3.28)0.34
  >60277 (69.3)123 (30.8)0.73 (0.51, 1.05)0.092119 (63.0)70 (37.0)158 (74.8)53 (35.1)
Sex
  Female286 (45.5)342 (54.5)131 (35.2)241 (64.8)155 (60.5)101 (39.5)
  Male445 (72.0)173 (28.0)2.93 (2.24, 3.83)<0.001207 (63.7)118 (36.3)3.28 (2.32, 4.66)<0.001238 (81.2)55 (18.8)2.79 (1.77, 4.42)<0.001
Ethnicity
  Malay440 (56.5)339 (43.5)196 (45.9)231 (54.1)244 (69.3)108 (30.7)
  Chinese157 (67.4)76 (32.6)0.98 (0.67, 1.43)0.90871 (56.3)55 (43.7)0.87 (0.53, 1.43)0.57686 (80.4)21 (19.6)1.13 (0.59, 2.16)0.674
  Indian105 (55.6)84 (44.4)0.71 (0.48, 1.05)0.08553 (47.3)59 (52.7)0.70 (0.43, 1.14)0.15152 (67.5)25 (32.5)0.79 (0.41, 1.54)0.713
  Others29 (64.4)16 (35.6)1.52 (0.75, 3.07)0.24118 (56.3)14 (43.8)1.51 (0.68, 3.35)0.31411 (84.6)2 (15.4)2.22 (0.38, 12.95)0.492
COVID-19 severity
  Mild264 (40.7)385 (59.3)171 (38.0)279 (62.0)93 (46.7)106 (53.3)
  Moderate123 (61.5)77 (38.5)1.66 (1.10, 2.50)0.01561 (56.5)47 (43.5)1.29 (0.74, 2.25)0.36362 (67.4)30 (32.6)1.85 (0.96, 3.57)0.067
  Severe344 (86.6)53 (13.4)3.17 (1.53, 6.57)0.002106 (76.3)33 (23.7)2.05 (0.68, 6.19)0.201238 (92.2)20 (7.8)4.54 (1.52, 13.54)0.007
Treatment
458 (78.0)129 (22.0)1.07 (0.63, 1.83)0.796162 (70.1)69 (29.9)2.36 (1.10, 5.03)0.027296 (83.1)60 (16.9)0.52 (0.21, 1.26)0.147
Types of treatment
  NSAID64 (79.0)17 (21.0)1.18 (0.60, 2.33)0.633176 (37.8)290 (62.2)0.55 (0.15, 2.05)0.37457 (83.9)11 (16.2)1.27 (0.49, 3.27)0.626
  HCQ16 (64.0)9 (36.0)1.22 (0.41, 3.63)0.72213 (59.1)9 (40.9)0.59 (0.16, 2.18)0.4313 (100.000
  Favipiravir140 (80.0)35 (20.0)1.51 (0.93, 2.47)0.0997 (53.8)6 (46.2)1.53 (0.74, 3.17)0.253100 (84.0)19 (16.0)1.47 (0.71, 3.03)0.297
  Methylpred110 (90.9)11 (9.1)1.40 (0.65, 3.02)0.39540 (71.4)16 (28.6)1.15 (0.41,3.28)0.78977 (95.1)4 (4.9)1.38 (0.38, 4.99)0.620
  Clexane220 (80.6)53 (19.4)1.35 (0.86, 2.11)0.19033 (82.5)7 (17.5)1.02 (0.51, 2.03)0.958167 (83.5)33 (16.5)1.39 (0.69, 2.78)0.358
  Tocilizumab97 (88.2)13 (11.8)1.25 (0.62, 2.51)0.52853 (72.6)20 (27.4)1.07 (0.46, 2.51)0.87959 (95.2)3 (4.8)1.30 (0.32, 5.37)0.717
  Dexamethasone379 (83.3)76 (16.7)1.38 (0.78, 2.44)0.26638 (79.2)10 (20.8)0.72 (0.32, 1.61)0.420260 (89.3)31 (10.7)2.07 (0.86, 5.01)0.106
Comorbidities
  CLD93 (80.9)22 (19.1)19.31 (2.38, 156.53)0.006119 (72.6)45 (27.4)12.61 (1.33, 119.46)0.02765 (91.5)6 (8.5)0.998
  NAFLD87 (73.1)21 (19.4)0.22 (0.03, 1.83)0.16058 (77.3)17 (22.7)0.41 (0.04, 4.10)0.44553 (89.8)6 (10.2)0.999
  DM285 (73.5)103 (26.5)0.94 (0.66, 1.36)0.75151 (76.1)16 (23.9)0.88 (0.52, 1.44)0.599172 (82.3)37 (17.7)0.93 (0.53, 1.64)0.813
  HTN323 (73.2)118 (26.8)1.64 (1.16, 2.33)0.005113 (63.1)66 (36.9)1.42 (0.89, 2.26)0.143195 (82.6)41 (17.4)2.13 (1.21, 3.75)0.009
  Other Comorbidities*731(67.6)84 (32.4)0.91 (0.64, 1.31)0.628128 (62.4)77 (37.6)1.03 (0.64, 1.67)0.90194 (76.4)29 (23.6)0.87 (0.48, 1.56)0.631
Ventilator
426 (47.8)466 (52.2)1.13 (0.69, 2.17)0.71065 (58.6)46 (41.4)0.75 (0.26, 2.15)0.589212 (91.8)19 (8.2)1.33 (0.54, 3.27)0.540
ICU admission
154 (89.5)18 (10.5)1.71 (0.86, 3.38)0.12493 (75.6)30 (24.4)2.69 (1.01, 6.70)0.03385 (96.6)3 (3.4)2.85 (0.70, 11.55)0.143
Death
51 (83.6)10 (16.4)1.04 (0.44, 2.43)0.93769 (82.1)15 (17.9)1.02 (0.34, 3.09)0.96630 (90.9)3 (9.1)0.94 (0.21, 4.16)0.934
Table 3

Multivarite analysis of COVID-19 patients with liver injury (n = 332)

CharacteristicsOverall
Cohort A
Cohort B
Liver injury
AOR (95% CI)p-valueLiver injury
AOR (95% CI)p-valueLiver injury
AOR (95% CI)p-value
YesNoYesNoYesNo
Age in years
  ≤ 60193 (22.8)653 (77.2)1.16 (0.81, 1.66)0.42162 (12.2)446 (87.8)0.66 (0.37, 1.19)0.166131 (38.8)207 (61.2)1.51 (0.92, 2.47)0.102
  >60139 (34.8)261 (65.3)57 (30.2)132 (69.8)82 (38.9)129 (61.1)
Sex
  Female122 (19.4)506 (80.6)39 (10.5)333 (89.5)83 (32.4)173 (67.6)
  Male210 (34.0)408 (66.0)1.79 (1.33, 2.41)<0.00180 (24.6)245 (75.4)2.45 (1.52, 3.95)<0.001130 (44.4)163 (55.6)1.53 (1.01, 2.32)0.048
Ethnicity
  Malay197 (25.3)582 (74.7)64 (15.0)363 (85.0)133 (37.8)219 (62.2)
  Chinese78 (33.5)155 (66.5)0.83 (0.56, 1.21)0.33129 (23.0)97 (77.0)0.64 (0.34, 1.21)0.16649 (45.8)58 (54.2)0.93 (0.55, 1.58)0.792
  Indian43 (22.8)146 (77.2)0.61 (0.39, 0.95)0.02919 (17.0)93 (83.0)0.80 (0.42, 1.52)0.49424 (31.2)53 (68.8)0.54 (0.29, 1.03)0.064
  Others14 (31.1)31 (77.2)1.50 (0.71, 3.20)0.2927 (21.9)25 (78.1)1.52 (0.55, 4.21)0.4237 (53.8)6 (46.2)1.48 (0.41, 5.33)0.547
COVID-19 severity
  Mild62 (9.6)587 (90.4).–35 (7.8)415 (92.2)27 (13.6)172 (86.4)
  Moderate56 (28.0)144 (72.0)3.03 (1.87, 4.92)0.00026 (24.1)82 (75.9)2.13 (1.04, 4.33)0.03830 (32.6)62 (67.4)3.26 (1.59, 6.70)0.001
  Severe214 (53.9)183 (46.1)4.56 (2.27, 9.18)0.00058 (41.7)81 (58.3)3.48 (1.09, 11.09)0.035156 (60.5)102 (39.5)4.71 (1.82, 12.19)0.001
Treatment
257 (43.8)330 (56.2)1.29 (0.72, 2.31)0.39080 (34.6)151 (65.4)3.74 (1.57, 8.93)0.003177 (49.7)179 (50.3)0.47 (0.19, 1.19)0.111
Types of treatment
  NSAID36 (44.4)45 (55.6)0.99 (0.57, 1.72)0.9701 (7.7)12 (92.3)0.12 (0.01, 1.14)0.06535 (51.5)33 (48.5)1.03 (0.52, 2.01)0.939
  HCQ10 (40.0)60.0 (60.0)1.57 (0.56–4.40)0.3897 (31.8)15 (68.2)0.66 (0.17–2.58)0.5623 (100.0)0.99 (−)
  Favipiravir70 (40.0)105 (60.0)0.91 (0.61, 1.35)0.62715 (26.8)41 (73.2)0.76 (0.36, 1.59)0.46055 (46.2)64 (53.8)0.89 (0.53, 1.48)0.649
  Methylpred74 (61.2)47 (38.8)1.39 (0.85, 2.28)0.19618 (45.0)22 (55.0)0.95 (0.41, 2.21)0.90356 (69.1)25 (30.9)1.64 (0.82, 3.29)0.163
  Clexane128 (46.9)145 (53.1)1.17 (0.80, 1.69)0.42024 (32.9)49 (67.1)0.88 (0.41, 2.21)0.716104 (52.0)96 (48.0)1.30 (0.79, 2.15)0.300
  Tocilizumab59 ( 53.6)51 (46.4)0.93 (0.31, 2.84)0.76721 (43.8)27 (56.3)1.02 (0.47, 2.21)0.95438 (61.3)24 (38.7)0.77 (0.37, 1.58)0.477
  Dexamethasone223 (49.0)232 (51.0)1.10 (0.63, 1.92)0.73560 (36.6)104 (63.4)0.59 (0.25, 1.37)0.216163 (56.0)128 (44.0)1.60 (0.68, 3.76)0.286
Comorbidities
  Chronic liver disease51 (44.3)64 (55.7)2.93 (1.04, 8.28).04320 (26.7)55 (73.3)7.32 (1.38, 38.84).01946 (64.8)25 (35.2)1.59 (0.43, 5.96).489
  NAFLD46 (42.6)62 (57.4)0.94 (0.31, 2.84).91716 (23.9)51 (76.1)0.26 (0.05, 1.56).14140 (67.8)19 (32.3)2.44 (0.58, 10.20).221
  Diabetes mellitus143 (36.9)245 (63.1)0.80 (0.67, 1.14).21440 (22.3)139 (77.7)0.44 (0.25, 0.79).006103 (49.3)106 (50.7)1.12 (0.70, 1.78).645
  Hypertension159 (36.1)282 (63.9)1.08 (0.77, 1.52).649152 (74.1)53 (25.9)1.31 (0.77, 2.24).327106 (44.9)130 (44.9)0.93 (0.57, 1.50).754
  Other Comorbidities*76 (34.1)147 (65.9)1.01 (0.70, 1.44).97440 (29.4)96 (70.6)1.38 (0.788, 2.44).26950 (40.7)73 (59.3)0.76 (0.46, 1.26).288
Ventilator
193 (54.5)161 (45.5)1.51 (0.89, 2.56).12950 (40.7)73 (59.3)0.73 (0.26, 2.02).540143 (61.9)88 (38.1)2.10 (1.10, 4.02).025
ICU admission
104 (60.5)68 (39.5)1.60 (0.99, 2.58).05441 (48.8)43 (51.2)2.75 (1.23, 6.19).01463 (71.6)25 (28.4)1.72 (0.84, 3.52).136
Death
34 (55.7)27 (44.3)1.25 (0.66, 2.38).48911 (39.3)17 (60.7)0.83 (0.29, 2.37).72723 (69.7)10 (30.3)1.84 (0.75, 4.55).184

Differences between cohort A and cohort B

In cohort B, patients were significantly older and more had diabetes mellitus (DM) and HTN compared to cohort A. The majority of patients in cohort A had mild disease (64.6%), whereas cohort B had significantly more patients with severe disease (47%) and required specific treatment, mechanical ventilation, and ICU admission. Notably, both ALB (71.6% vs. 48.5%, p < 0.001) and LI (38.8% vs. 17.1%, p < 0.001) were more prevalent in cohort B patients. The mean value of ALT and AST is consistently higher in cohort B across all severity of disease for both ALB and LI. Cohort B patients with ALB had significantly higher mean values of ALT, AST, and GGT, whereas ALT and GGT were significantly higher in those with LI (Fig. 1). The mean values of ALT and AST were consistently higher in cohort B across all severities of disease for both ALB and LI (Figs. 2 and 3).

Liver biochemistry of COVID-19 patients with abnormal liver biochemistry and liver injury.
Fig. 1  Liver biochemistry of COVID-19 patients with abnormal liver biochemistry and liver injury.

*Significant difference of mean value compared with cohort A (p < 0.05). ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma glutamyl transpeptidase.

Liver biochemistry of COVID-19 patients with abnormal liver biochemistry and differing disease severity.
Fig. 2  Liver biochemistry of COVID-19 patients with abnormal liver biochemistry and differing disease severity.

*Significant difference of mean value compared with cohort A (p < 0.05). ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma glutamyl transpeptidase.

Liver biochemistry of COVID-19 patients with liver injury and differing disease severity.
Fig. 3  Liver biochemistry of COVID-19 patients with liver injury and differing disease severity.

*Significant difference of mean value compared with cohort A (p < 0.05). ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma glutamyl transpeptidase.

Multivariate analysis of cohort A found a significantly higher risk of developing both ALB and LI in male patients, those with underlying CLD, who received specific disease-modulating treatment, or who required ICU admission. Additionally, patients in cohort A with moderate or severe disease had a significantly higher risk of developing LI, with a lesser risk in DM patients (Tables 2 and 3). In cohort B, multivariate analysis identified male sex, moderate or severe disease, and HTN as factors that increased the risk of ALB. Male sex, moderate or severe disease, and requiring mechanical ventilation increased the risk of LI (Tables 2 and 3).

Discussion

From our data, the incidence of mild liver dysfunction in the form of ALB was common (58.7%) among COVID-19 patients. Worldwide, the incidence of mild liver dysfunction ranges from 11.0% to 76.3%.12,14,16,19–27 Lack of a standard definition of liver dysfunction and heterogeneity of the study population probably contribute to the wide variation. Elevated ALT, AST, and GGT had nearly the same incidence, 36.83%, 34.99%, and 34.91% respectively, which mirrors the findings in other studies that included GGT in the analysis.25,27 Our data also showed that severe liver dysfunction, represented by LI (26.6%) was less common, and liver failure (1.1%) was very rare in these hospitalized COVID-19 patients. A similar frequency of severe liver dysfunction was reported by Cai et al.16 and Phipps et al.19 at 21.5% and 27.4%, respectively. Clinical characteristics that were significantly associated with LI were male sex, moderate and severe COVID-19 infection, and underlying CLD.

Several possibilities for liver dysfunction in COVID-19 infection have been suggested. Firstly, SARS-COV-2 virus has been shown to have a direct cytopathic effect on hepatocytes and cholangiocytes.11,17,28,29 This is supported by presence of SARS-CoV 2-interacting host receptors such as angiotensin-converting enzyme 2, transmembrane serine protease 2, and paired basic amino acid cleaving enzyme, which is expressed at varying levels in hepatocytes, cholangiocytes, and periportal liver sinusoidal endothelial cells.30,31 Also, as enterocytes are able to bind angiotensin-converting enzyme 2, there is a high possibility of portal vein viremia leading to an increased likelihood of a direct cytopathic effect.30 Furthermore, analysis of liver samples from two deceased COVID-19 patients with elevated liver enzymes demonstrated the presence of intact viral particles in the cytoplasm of hepatocytes.32 Secondly, pre-existing CLD may be a contributing factor for liver dysfunction in COVID-19 infection. CLD in COVID-19 patients is a well-established risk factor for developing severe liver dysfunction,16,33–35 which is also reflected in our study findings (Tables 2 and 3). However, two other studies reported that CLD was not a significant risk factor for developing liver dysfunction.19,27 This could be attributed to the inclusion of nonalcoholic fatty liver disease which represents the majority of CLD patients and the low prevalence of CLD among the study patients17 as well as the small number of patients in the study.27 Thirdly, drug-induced LI has been postulated to cause abnormal liver function in COVID-19 patients. The use of disease-modulating pharmacotherapy such as hydroxychloroquine (HCQ),17 lopinavir/ritonavir,16 or even tocilizumab11,28,29 in moderate and severe COVID-19 infection has been widely reported to cause drug-induced LI. Cohort A patients, who were treated with disease-modulating drugs, were found to have significantly increased occurrences of ALB and LI, but this trend was not observed in cohort B patients. One possible explanation for this would be the use of HCQ in our center during the early wave of COVID-19 infection which fell out of favor thereafter. Hundt et al.20 reported significant liver dysfunction with the use of HCQ, but another center reported no increase in liver dysfunction associated with HCQ.27

Additional factors that have been postulated to cause liver dysfunction in COVID-19 infection are cytokine storm, ischemic hepatitis, and liver congestion associated with mechanical ventilation.17,28,29 In our study, LI was more frequent in Delta-variant patients who required ventilatory support than in those who did not require it. Mechanical ventilation19,20 and the presence of cytokine storm, in which inflammatory markers such as interleukin-6 and ferritin are elevated have been associated with significant liver dysfunction.19 The presence of these factors usually implies severe COVID-19 infection. This is in line with our data that showed patients with moderate and severe COVID-19 infection were more likely to develop ALB and LI. Multiple studies have demonstrated that the severity of liver dysfunction was proportionate to the severity of COVID-19 infection.19,20,26,27

Apart from the severity of illness and presence of CLD, male sex increased the likelihood of developing ALB and LI. Other studies have reported significantly higher liver dysfunction in men.20,27 Previous studies have shown that men tended to have a more severe course of illness than women. This was possibly due to several factors such as the difference in sex-related immunological response driven by sex hormones and the X chromosome as well as a high expression of coronavirus receptors (angiotensin-converting enzyme 2) in men.36,37 Less healthy lifestyle options such as higher levels of smoking and drinking among men than in women may also be a contributing factor.

Only a handful of studies have analyzed the clinical characteristics of the Delta variant. Budhiraja et al.,38 who reviewed nearly 20,000 COVID-19 patients, found that almost 40% of Delta-variant patients had a severe course of disease with significantly increased need of ICU admission, oxygen support, and use of remdesivir, steroids, intravenous immunoglobulin, and enoxaparin. Interestingly, a significant difference in age was not observed, although presence of the Delta variant was notably higher in male patients and in those with DM and HTN.38 Al Bahrani et al.,39 who analyzed 619 patients, reported those infected with the Delta variant were significantly older but reported a similar need of ICU admission, use of mechanical ventilation, and use of methylprednisolone for both groups of patients. The mortality rate among Delta-variant patients was lower than the rates in patients with other VoCs.

The frequency of ALB and LI was higher among patients with Delta variant COVID-19 infection (cohort B) compared with predecessor strains (cohort A). In particular, transaminitis was higher in patients infected with Delta variant compared with predecessor strains across all categories of severity for both ALB and LI. Al Bahrani et al.39 reported similar findings, where ALT and AST were significantly higher in patients infected with the Delta variant.39 Differences in admission criteria that led to differences in the baseline demographics of the cohorts may have contributed to significantly higher ALB and LI rates in patients with mild disease in cohort B than in cohort A, as this would have excluded a proportion of asymptomatic Delta variant patients who most likely would have had no or very slight liver derangement. However, the reason for the higher proportion of ALB and LI among Delta variant patients with moderate and severe disease is not well understood. A possible explanation is that Delta variant has a higher affinity to hepatocytes and cholangiocytes which results in a higher incidence of hepatitis and cholestasis. The Delta variant has a higher cell affinity with better cell fusion and enhanced cell entry.4,40 Arora et al.40 demonstrated the Delta variant to have enhanced lung and colon cell entry, resulting in more tissue damage and higher virulence than previous variants. This could likely result in a higher burden of portal vein viraemia, further increasing the risk of damage to hepatocytes and cholangiocytes.

This study has some limitations. As the study population is based on convenience sampling, some of the patients with mild disease and relatively short stays with normal LFTs on admission do not have a repeat blood test. Hence, there could be a small proportion of patients who developed liver dysfunction during hospitalization that was not captured in the data. Furthermore, for this same reason, baseline and peak abnormalities of LFT could not be compared. Differences in admission criteria for both cohorts also led to sampling bias among patients with mild disease in this study. As this is a single-center study in an urban area, these data may not be representative of patients in a semi-urban or rural setting. Additionally, vaccination history, which may contribute to liver dysfunction, was not included due to a lack of data.

Conclusions

ALB among COVID-19 patients is common. However, LI is less common among COVID-19 patients. Risk factors that are more likely to be associated with the development of LI were male sex, with moderate and severe COVID-19 infection, underlying CLD, and Delta variant COVID-19 infection.

Abbreviations

ALB: 

abnormal liver biochemistry

ALP: 

alkaline phosphatase

ALT: 

alanine transaminase

AST: 

aspartate transaminase

CI: 

confidence interval

CLD: 

chronic liver disease

COVID-19: 

coronavirus disease of 2019

DM: 

diabetes mellitus

GGT: 

gamma glutamyl transferase

HCQ: 

hydroxychloroquine

HTN: 

hypertension

ICU: 

intensive care unit

LFT: 

liver function test

LI: 

liver injury

NAFLD: 

nonalcoholic fatty liver disease

OR: 

odds ratio

RT-PCR: 

real-time polymerase chain reaction

SARS-CoV 2: 

severe acute respiratory syndrome coronavirus 2

VoC: 

variant of concern

Declarations

Acknowledgement

We would like to thank the clinic and nursing staff of the Medical Outpatient Department, UMMC, for their assistance during the performance of this study.

Ethical statement

This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Research Ethics Committee of University of Malaya (MECID No. 202146-10036). All subjects gave written informed consent.

Data sharing statement

The dataset used in this study is not available publicly, but is available from the principle author at [email protected].

Funding

None.

Conflict of interest

The authors have no conflict of interests related to this publication.

Authors’ contributions

Study design (RBR and SM), data collection (RPS, NP, AK, BMJ, SB, RXN, HCO and PLW), data interpretation (RBR and XHK), manuscript drafting (RBR), and critical revision of manuscript content (SM, SFSO and SP). All authors made a significant contribution to this study and have approved the final manuscript.

References

  1. Hashim JH, Adman MA, Hashim Z, Mohd Radi MF, Kwan SC. COVID-19 Epidemic in Malaysia: Epidemic Progression, Challenges, and Response. Front Public Health 2021;9:560592 View Article PubMed/NCBI
  2. Aleem A, Akbar Samad AB, Vaqar S. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 View Article PubMed/NCBI
  3. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as of June 2021. Euro Surveill 2021;26(24):2100509 View Article PubMed/NCBI
  4. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 2021;599(7883):114-119 View Article PubMed/NCBI
  5. Kuzmina A, Wattad S, Khalaila Y, Ottolenghi A, Rosental B, Engel S, et al. SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. iScience 2021;24(12):103467 View Article PubMed/NCBI
  6. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J 2021;97(1147):312-320 View Article PubMed/NCBI
  7. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020;215:108427 View Article PubMed/NCBI
  8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;324(8):782-793 View Article PubMed/NCBI
  9. Yu D, Du Q, Yan S, Guo XG, He Y, Zhu G, et al. Liver injury in COVID-19: clinical features and treatment management. Virol J 2021;18(1):121 View Article PubMed/NCBI
  10. Wu J, Song S, Cao HC, Li LJ. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J Gastroenterol 2020;26(19):2286-2293 View Article PubMed/NCBI
  11. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int 2020;40(6):1278-1281 View Article PubMed/NCBI
  12. Qi X, Liu C, Jiang Z, Gu Y, Zhang G, Shao C, et al. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. J Hepatol 2020;73(2):455-458 View Article PubMed/NCBI
  13. Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne) 2021;8:651658 View Article PubMed/NCBI
  14. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5(5):428-430 View Article PubMed/NCBI
  15. Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: An A-Z literature review. Dig Liver Dis 2021;53(2):146-152 View Article PubMed/NCBI
  16. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;73(3):566-574 View Article PubMed/NCBI
  17. Li Y, Xiao SY. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications. J Med Virol 2020;92(9):1491-1494 View Article PubMed/NCBI
  18. Saini RK, Saini N, Ram S, Soni SL, Suri V, Malhotra P, et al. COVID-19 associated variations in liver function parameters: a retrospective study. Postgrad Med J 2022;98(1156):91-97 View Article PubMed/NCBI
  19. Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, et al. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology 2020;72(3):807-817 View Article PubMed/NCBI
  20. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology 2020;72(4):1169-1176 View Article PubMed/NCBI
  21. Voiosu A, Roman A, Pop R, Boeriu A, Popp C, Zurac S, et al. Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience. Rom J Intern Med 2022;60(1):49-55 View Article PubMed/NCBI
  22. Schattenberg JM, Labenz C, Wörns MA, Menge P, Weinmann A, Galle PR, et al. Patterns of liver injury in COVID-19 - a German case series. United European Gastroenterol J 2020;8(7):814-819 View Article PubMed/NCBI
  23. Piano S, Dalbeni A, Vettore E, Benfaremo D, Mattioli M, Gambino CG, et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver Int 2020;40(10):2394-2406 View Article PubMed/NCBI
  24. Chaibi S, Boussier J, Hajj WE, Abitbol Y, Taieb S, Horaist C, et al. Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort. Clin Res Hepatol Gastroenterol 2021;45(5):101556 View Article PubMed/NCBI
  25. Kalal CR, Joshi H, Kumar V, Gopal D, Rathod D, Shukla A, et al. Clinical Significance of Liver Function Abnormality in Patients with COVID-19: A Single-center Experience from Western India. J Clin Transl Hepatol 2021;9(6):878-888 View Article PubMed/NCBI
  26. Saithanyamurthi HV, Munirathinam M, Ananthavadivelu M. Prevalence of liver injury in 445 patients with Corona Virus Disease-19-Single-centre experience from southern India. Indian J Gastroenterol 2021;40(3):303-308 View Article PubMed/NCBI
  27. Guo H, Zhang Z, Zhang Y, Liu Y, Wang J, Qian Z, et al. Analysis of liver injury factors in 332 patients with COVID-19 in Shanghai, China. Aging (Albany NY) 2020;12(19):18844-18852 View Article PubMed/NCBI
  28. Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol 2020;10(3):263-265 View Article PubMed/NCBI
  29. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol 2020;5(6):529-530 View Article PubMed/NCBI
  30. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int 2021;41(1):20-32 View Article PubMed/NCBI
  31. Pirola CJ, Sookoian S. SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19. Liver Int 2020;40(8):2038-2040 View Article PubMed/NCBI
  32. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020;73(4):807-816 View Article PubMed/NCBI
  33. Martinez MA, Franco S. Impact of COVID-19 in Liver Disease Progression. Hepatol Commun 2021;5(7):1138-1150 View Article PubMed/NCBI
  34. Nagarajan R, Krishnamoorthy Y, Rajaa S, Hariharan VS. COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis. Prev Chronic Dis 2022;19:E53 View Article PubMed/NCBI
  35. Qi RB, Wu ZH. Association between COVID-19 and chronic liver disease: Mechanism, diagnosis, damage, and treatment. World J Virol 2023;12(1):22-29 View Article PubMed/NCBI
  36. Fabião J, Sassi B, Pedrollo EF, Gerchman F, Kramer CK, Leitão CB, et al. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Braz J Med Biol Res 2022;55:e11711 View Article PubMed/NCBI
  37. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women?. SN Compr Clin Med 2020;2(7):874-876 View Article PubMed/NCBI
  38. Budhiraja S, Indrayan A, Aggarwal M, Jha V, Jain D, Tarai B. Differentials in the characteristics of COVID-19 cases in Wave-1 and Wave-2 admitted to a network of hospitals in North India. medRxiv 2021 View Article PubMed/NCBI
  39. AlBahrani S, AlAhmadi N, Hamdan S, Elsheikh N, Osman A, Almuthen S, et al. Clinical Presentation and Outcome of Hospitalized Patients With COVID-19 in the First and Second Waves in Saudi Arabia. Int J Infect Dis 2022;118:104-108 View Article PubMed/NCBI
  40. Arora P, Sidarovich A, Krüger N, Kempf A, Nehlmeier I, Graichen L, et al. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Rep 2021;37(2):109825 View Article PubMed/NCBI